Compare BCX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCX | PCRX |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.8M | 949.9M |
| IPO Year | N/A | 2010 |
| Metric | BCX | PCRX |
|---|---|---|
| Price | $13.19 | $25.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | 155.2K | ★ 612.0K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 6.99% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | N/A | $8.54 |
| P/E Ratio | ★ N/A | $134.37 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $9.68 | $18.80 |
| 52 Week High | $13.86 | $27.66 |
| Indicator | BCX | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.35 | 55.42 |
| Support Level | $11.90 | $22.16 |
| Resistance Level | $13.37 | $27.08 |
| Average True Range (ATR) | 0.21 | 0.75 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 88.35 | 94.46 |
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies, or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.